alexa
Reach Us +14-703-471-923
The Bright Future of Liposome Mediated Drug Delivery | OMICS International
ISSN: 2168-9652
Biochemistry & Physiology: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

The Bright Future of Liposome Mediated Drug Delivery

Dandan Hu1, Shukun Tang1, Haisheng Peng1,2* and Qun Wang2*
1Department of Pharmaceutics, Daqing Campus, Harbin Medical University, 1 Xin Yang Road Daqing, 163319, China
2Department of Chemical and Biological Engineering, Iowa State University, Ames, IA 50011, USA
Corresponding Authors : Haisheng Peng
Department of Pharmaceutics
Daqing Campus of Harbin Medical University
1 Xinyang Rd Daqing, 163319, China
Tel: +86-459-8153 003
Fax: +86-459-8977 588
E-mail: [email protected]
  Qun Wang
Department of Chemical and Biological Engineering
Iowa State University, 2114 Sweeney Hall
Ames, Iowa 50011, USA
Tel: (515) 294-4218
Fax: (515) 294-8216
E-mail: qunwang
Received February 17, 2015; Accepted February 18, 2015; Published February 25, 2015
Citation: Hu D, Tang S, Peng H, Wang Q (2015) The Bright Future of Liposome Mediated Drug Delivery. Biochem Physiol 4:e133. doi:10.4172/2168-9652.1000e133
Copyright: © 2015 Hu D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Biochemistry & Physiology: Open Access

Abstract

There are many problems for conventional therapy which may be circumvented when using specific drug delivery systems to achieve the desired clinical results. Among the various delivery systems being investigated, liposomes hold great promise. The liposomes not only have a variety of structural characteristics, but can enlarge their scope of drugs to get their optimized pharmacological effects. In addition, it can be functionalized to target specific tissues [1].
Target strategy has been a good approach for oligonucleotides delivery to the pathological sites [2]. Today, more people have devoted themselves to design the targeted liposomes with receptor- mediated or antibody-mediated drug delivery systems. For example, the MicroRNA- 1(miR-1) has been detected in cardiac and skeletal tissues. Moreover, it is overexpressed in ischemic cardiac tissues. The downregulation of miR-1 could relieve arrhythmogenesis via the anti-miR-1 antisense oligonucleotides (AMO-1). As a result, researchers explored the applications of liposomes modified with anti-cardiac troponin I (cTn I) antibody. According to the in vivo image that evaluated the targeting abilities to foci, they found that it was effective for targeting ischemic myocardium tissues by loading AMO-1 into the modified liposomes (cT-A-LIP) and delivering the oligonucleotides to the affected heart (Figure 1). According to the paper, Liu and her colleagues not only confirmed that cT-A-LIP delivered AMO-1 to ischemic myocardium, but concluded that AMO-1 alleviated ischemic arrhythmia by silencing miR-1 in ischemic myocardium and restoring the depolarized resting pellicle potential (RMP) in MI rats [3]. Tang et al. [4] have also confirmed that liposomes drug delivery system improved the drug targeting on the ischemic heart tissue and myocardiopathy.
As time went by, we will set into a period of aging. In order to keep healthy, we should pay attention to the central nervous system (CNS) diseases. It is a major challenge to find effective treatment moduli for central nervous diseases because of the presence of the blood brain barrier (BBB). Another major problem is how to achieve the special region delivery of therapeutics. According to these existing problems, many studies have found that liposomes modified with p-aminophenyla- D-mannopyranoside (MAN-LIP) could target the brain. Hao et al. have confirmed that glucose transporters (GLUT) can facilitate MANLIP to cross the BBB. They also found that MAN-LIP can target the cortex, cerebellum, brainstem, brainstem, hippocampus and pontine nuclei [5]. The experimental data demonstrated that MAN-LIP not only improved the brain delivery, but targeted intracerebral regions, particularly, in the cerebellum and cerebral cortex. Du et al. have indicated that both GLUT1 and GLUT3 have influenced on the brain delivery of MAN-LIP [6]. According to above results, we conclude that MAN-LIP is a promising brain drug delivery system which could improve brain delivery by targeting select brain functional regions.
With the development of nanotechnology, we have made tremendous progress in cancer research, especially in novel diagnostics and treatment [7-11]. However, there are big challenges to treat cancer. For example, the cancer chemotherapy could form severe side effects, such as myelosuppression [12]. As we know, target therapy may be the most efficient way to deliver the cytotoxic agents to tumor tissue and minimize undesired side effects of these drugs. Liposome is widely used drug delivery systems. It can change the pharmacokinetics and bio-distribution of encapsulated drugs. As drug carriers, the unmodified and modified liposomes can be used to treat a wide variety of cancers [13]. For instance, Li’s research has revealed that liposomes modified with daunorubicin plus tamoxifen changed the plasma pharmacokinetics and bio-distribution of drugs in the breast cancer murine models [14]. Takeuchi et al. [12] showed that liposomes modified with cetylated polyethylenimine (cetyl-PEI) were more effective than unmodified liposomes. Divya’s studies suggested that liposomes modified with lactobionic acid (LA-LIP) were effective to the hepatocellular carcinoma (HCC). The uptake and organ distribution of the LA-LIP revealed that loaded drug prominently accumulated in the tumor. The results showed that liposome were a successful carrier for HCC targeting [15]. In conclusion, liposome is a promising carrier for targeted drug delivery in treating cancers.
The formation of hepatic failure has many reasons. One reason is the inflammatory cytokines produced by Kupffer cells which are related to endotoxin syndrome. It was reported that the acute or chronic conditions of hepatic failure is fatal to our lives [16]. We knew that liposomes could be utilized for effective targeting delivery by receptor-mediated endocytosis [15]. Higuchi et al. [17] showed that Kupffer cell-selective oligonucleotide could be carried through novel Fucose modified liposomes (Fuc-LIP) due to the recognition of fucose receptors on Kupffer cells. According to the cytokines production, liver injury was prevented by Fuc-LIP at the same time. In addition, Fuc- LIP played a significant role in treating fatal inflammatory liver disease which was associated with cytokine [17]. So, liposome is a promising approach for targeting liver diseases.
Inherited kidney diseases and common renal diseases can cause interstitial fibrosis, tubular atrophy, and glomerulosclerosis. However, it is difficult for gene delivery to the kidney due to the characteristics of renal cell biology. According to non-viral vectors, the liposome is a good candidate for kidney targeted gene therapy [18]. Lai et al. [19] have compared three different routes of liposome-mediated gene delivery to the kidney in mice: intra-renal-pelvic, intra-renal-arterial, and intra-renal-parenchymal injections. For mouse model, intrarenal- pelvic administration was more feasible than intra-renal-arterial injection. However, in humans, catheterization via renal arteries or renal pelvis directly could realize gene delivery. For liposome-mediated gene delivery, it is a possible route of intra-renal-pelvic or intra-renalarterial which transfers gene sequence to renal tubular epithelial cells. Therefore, liposomes mediated gene therapy is a promising treatment for patients affected by hereditary kidney diseases [19].
It has been demonstrated that modified liposome is an effective way to target heart, liver, kidney, brain, lung and bone [20,21]. For cancers, there are plenty of papers to discuss the therapy of breast cancer and liver cancer using the modified liposome. People have admitted that liposome is a versatile drug carrier. Liposomes mediated drug delivery has wide range applications and functions, including using a specific cell ligand targeted on their surface because of the facile change of structure. Liposomes mediated drug delivery also has some disadvantages. The main problem is that it is impossible to cross most regular pellicle barriers due to their imposed size. Nonetheless, with the development of liposome technology, liposomes mediated drug delivery will play a more important role in clinical environment in the future [1].
References

Figures at a glance

Figure
Figure 1
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 12544
  • [From(publication date):
    March-2015 - Jan 23, 2019]
  • Breakdown by view type
  • HTML page views : 8720
  • PDF downloads : 3824

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2019-20
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri and Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

ankara escort

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

pendik escort

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2019 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version